XBIO SCHEDULE 13G/A: SEC filing
Filed with the SEC on · accession 0001037389-26-000072
XBIO filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 12, 2026. Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation filed an amended Schedule 13G reporting beneficial ownership of 55,040 shares, or 2.35%, of Xenetic Biosciences, Inc. common stock as of July 1, 2026. The stock moved -9.2% by the first close after the filing.
Summary of the filing
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation filed an amended Schedule 13G reporting beneficial ownership of 55,040 shares, or 2.35%, of Xenetic Biosciences, Inc. common stock as of July 1, 2026. The filing is a passive investment disclosure and does not indicate any intent to influence control of the company.
Key details
How XBIO stock reacted
Close before
$1.84
Nov 11, 2026
First close after
-9.24%
$1.67
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for XBIO, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for XBIO?
Click hereFrequently asked questions
What did XBIO file with the SEC on Nov 12, 2026?
XBIO filed a SCHEDULE 13G/A (SEC filing). Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation filed an amended Schedule 13G reporting beneficial ownership of 55,040 shares, or 2.35%, of Xenetic Biosciences, Inc. common stock as of July 1, 2026. The filing is a passive investment disclosure and does not indicate any intent to influence control of the company.
How do I read a SCHEDULE 13G/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).
How did XBIO stock react to this filing?
XBIO closed at $1.84 before the filing and $1.67 on Nov 12, 2026 (-9.24%).
Other XBIO SEC filings
Get alerts when XBIO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days